eng Oriental Scientific Publishing Company Biosciences Biotechnology Research Asia 0973-1245 2020-09-25 17 3 499 506 10.13005/bbra/2853 37131 article Belapurkar Pranoti 1 Goyal Pragya 2 Department of Biosciences, Acropolis Institute, Mangliya, Indore, Madhya Pradesh, India Department of Biotechnology, IPS Academy, Indore, Madhya Pradesh, India The COVID- 19 pandemic has made the scientists today all around the globe to look for its specific prevention and treatment modalities. The disease presents itself as asymptomatic to mild to severe respiratory symptoms along with lesser common gastrointestinal symptoms of diarrhea, nausea, and vomiting. The situation worsens due to lack of precise treatment strategy. The Healthcare system is being overwhelmed, emphasizing on the need to look for alternate supportive therapy that can not only enhance the immune status of people worldwide but at the same time, ensure better prognosis. The relationship between the gut microbiota and upper and lower respiratory tract viral infections are well studied. Oral administration of probiotic microorganisms of genera Lactobacillus, Bifidobacterium and Bacillusin mice suffering from influenza infection have shown increased TNFα, IFN-γ and NK cell responses along with the production of anti-Influenza IgG. At the same time they have shown immunomodulation by producing anti-inflammatory cytokines as well as cytotoxic T-cells and T-suppressor cells. Hence, probiotic strains of generaLactobacillus, Bifidobacterium and Bacillushave shown a probability to be used as preventive and therapeutic agents for SARS- CoV-2. https://www.biotech-asia.org/vol17no3/probiotics-an-alternative-therapeutic-strategy-for-covid-19/ COVID-19; Dysbiosis; Gut microbiota; Probiotics; Respiratory tract infections